We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Quest Diagnostics (DGX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Quest Diagnostics is a member of the Medical sector. This group includes 946 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Quest Diagnostics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for DGX's full-year earnings has moved 0.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, DGX has moved about 16.9% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.6% on average. This shows that Quest Diagnostics is outperforming its peers so far this year.
Another stock in the Medical sector, Elicio Therapeutics (ELTX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 58.4%.
Over the past three months, Elicio Therapeutics' consensus EPS estimate for the current year has increased 5.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Quest Diagnostics belongs to the Medical - Outpatient and Home Healthcare industry, which includes 15 individual stocks and currently sits at #56 in the Zacks Industry Rank. On average, this group has gained an average of 7.6% so far this year, meaning that DGX is performing better in terms of year-to-date returns.
In contrast, Elicio Therapeutics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 464 stocks and is ranked #96. Since the beginning of the year, the industry has moved +20.8%.
Investors with an interest in Medical stocks should continue to track Quest Diagnostics and Elicio Therapeutics. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Quest Diagnostics (DGX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Quest Diagnostics is a member of the Medical sector. This group includes 946 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Quest Diagnostics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for DGX's full-year earnings has moved 0.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, DGX has moved about 16.9% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.6% on average. This shows that Quest Diagnostics is outperforming its peers so far this year.
Another stock in the Medical sector, Elicio Therapeutics (ELTX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 58.4%.
Over the past three months, Elicio Therapeutics' consensus EPS estimate for the current year has increased 5.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Quest Diagnostics belongs to the Medical - Outpatient and Home Healthcare industry, which includes 15 individual stocks and currently sits at #56 in the Zacks Industry Rank. On average, this group has gained an average of 7.6% so far this year, meaning that DGX is performing better in terms of year-to-date returns.
In contrast, Elicio Therapeutics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 464 stocks and is ranked #96. Since the beginning of the year, the industry has moved +20.8%.
Investors with an interest in Medical stocks should continue to track Quest Diagnostics and Elicio Therapeutics. These stocks will be looking to continue their solid performance.